Table 1 Overview of the assays used in this study to assess extracellular matrix turnover
From: Accelerated extracellular matrix turnover during exacerbations of COPD
Assay | Target | Detection range (ng/ml) | Intra-and inter-assay variation (%) | Reference level (ng/ml), mean (SD) | References |
|---|---|---|---|---|---|
C3M | Collagen type III degraded by MMPs | 5.52–177 | 3.4 and 9.8 | 15.3 (3.8) | [28] |
C4M | Collagen type IV degraded by MMPs | 22.8–748 | 4.2 and 18.5 | 55.4 (17.8) | [29] |
C6M | Collagen type VI degraded by MMPs | 4.88–420 | 8.0 and 11.0 | 8.85 (5.1) | [30] |
ELM7 | Elastin degraded by MMP-7 | 1.16–36.6 | 8.1 and 9.1 | 2.23 (0.74) | Preliminary data |
EL-NE | Elastin degraded by neutrophil elastase | 1.76–167 | 8.6 and 12.9 | 4.09 (2.24) | [31] |
VCANM | Versican degraded by MMPs | 0.78–7.13 | 3.0 and 7.6 | 1.20 (0.23) | [32] |
Pro-C3 | Collagen type III propeptide (N-terminal) | 5.32–96.4 | 6.5 and 12.4 | 12.3 (4.4) | [33] |
P4NP 7S | Collagen type IV 7S domain | 32.9–3460 | 9.4 and 14.2 | 263 (91.3) | [34] |
Pro-C6 | Collagen type VI C5 domain | 0.30–117 | 4.8 and 15.2 | 4.37 (0.69) | Preliminary data |